Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Equity Ratio (2021 - 2025)

Amylyx Pharmaceuticals has reported Equity Ratio over the past 5 years, most recently at 0.92 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.92 for Q4 2025, up 7.85% from a year ago — trailing twelve months through Dec 2025 was 0.92 (up 7.85% YoY), and the annual figure for FY2025 was 0.92, up 7.85%.
  • Equity Ratio for Q4 2025 was 0.92 at Amylyx Pharmaceuticals, roughly flat from 0.92 in the prior quarter.
  • Over the last five years, Equity Ratio for AMLX hit a ceiling of 0.92 in Q4 2025 and a floor of 1.43 in Q4 2021.
  • Median Equity Ratio over the past 5 years was 0.86 (2022), compared with a mean of 0.72.
  • Biggest five-year swings in Equity Ratio: surged 160.79% in 2022 and later dropped 12.73% in 2024.
  • Amylyx Pharmaceuticals' Equity Ratio stood at 1.43 in 2021, then surged by 160.79% to 0.87 in 2022, then decreased by 3.73% to 0.84 in 2023, then grew by 1.59% to 0.85 in 2024, then rose by 7.85% to 0.92 in 2025.
  • The last three reported values for Equity Ratio were 0.92 (Q4 2025), 0.92 (Q3 2025), and 0.86 (Q2 2025) per Business Quant data.